Details

Autor(en) / Beteiligte

• Wiebe, C.
• Gibson, I. W.
• Blydt‐Hansen, T. D.
• Pochinco, D.
• Birk, P. E.
• Ho, J.
• Karpinski, M.
• Goldberg, A.
• Storsley, L.
• Rush, D. N.
• Nickerson, P. W.

Titel

Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor‐Specific Antibody

Ist Teil von

• American journal of transplantation, 2015-11, Vol.15 (11), p.2921-2930

Ort / Verlag

United States: Elsevier Limited

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Understanding rates and determinants of clinical pathologic progression for recipients with de novo donor‐specific antibody (dnDSA), especially subclinical dnDSA, may identify surrogate endpoints and inform clinical trial design. A consecutive cohort of 508 renal transplant recipients (n = 64 with dnDSA) was studied. Recipients (n = 388) without dnDSA or dysfunction had an eGFR decline of −0.65 mL/min/1.73 m2/year. In recipients with dnDSA, the rate eGFR decline was significantly increased prior to dnDSA onset (−2.89 vs. −0.65 mL/min/1.73 m2/year, p < 0.0001) and accelerated post‐dnDSA (−3.63 vs. −2.89 mL/min/1.73 m2/year, p < 0.0001), suggesting that dnDSA is both a marker and contributor to ongoing alloimmunity. Time to 50% post‐dnDSA graft loss was longer in recipients with subclinical versus a clinical dnDSA phenotype (8.3 vs. 3.3 years, p < 0.0001). Analysis of 1091 allograft biopsies found that dnDSA and time independently predicted chronic glomerulopathy (cg), but not interstitial fibrosis and tubular atrophy (IFTA). Early T cell–mediated rejection, nonadherence, and time were multivariate predictors of IFTA. Independent risk factors for post‐dnDSA graft survival available prior to, or at the time of, dnDSA detection were delayed graft function, nonadherence, dnDSA mean fluorescence intensity sum score, tubulitis, and cg. Ultimately, dnDSA is part of a continuum of mixed alloimmune‐mediated injury, which requires solutions targeting T and B cells. In this study, the authors analyze clinical and histologic risk factors available at the time of de novo donor‐specific antibody detection to determine clinical and histologic predictors of subsequent allograft failure, and their importance for clinical trial design.